Barclays PLC Has $13.61 Million Stake in 10x Genomics, Inc. (NASDAQ:TXG)

Barclays PLC increased its position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 11.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 602,536 shares of the company's stock after purchasing an additional 63,079 shares during the period. Barclays PLC owned approximately 0.50% of 10x Genomics worth $13,605,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC raised its position in shares of 10x Genomics by 134.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,637 shares of the company's stock valued at $32,000 after buying an additional 939 shares in the last quarter. GAMMA Investing LLC increased its stake in 10x Genomics by 451.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company's stock worth $35,000 after acquiring an additional 1,265 shares during the period. Capital Performance Advisors LLP acquired a new position in 10x Genomics in the 3rd quarter valued at $35,000. First Horizon Advisors Inc. lifted its position in shares of 10x Genomics by 74.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company's stock valued at $37,000 after acquiring an additional 808 shares during the period. Finally, Blue Trust Inc. grew its holdings in shares of 10x Genomics by 136.5% during the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company's stock worth $40,000 after purchasing an additional 1,025 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently commented on TXG shares. Canaccord Genuity Group dropped their price target on 10x Genomics from $32.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, October 10th. UBS Group reduced their price target on shares of 10x Genomics from $25.00 to $20.00 and set a "neutral" rating on the stock in a research report on Wednesday, October 30th. Stephens restated an "overweight" rating and set a $30.00 price objective on shares of 10x Genomics in a research report on Thursday, October 10th. Barclays reduced their target price on 10x Genomics from $21.00 to $19.00 and set an "overweight" rating on the stock in a report on Friday, November 1st. Finally, Leerink Partners began coverage on 10x Genomics in a research note on Tuesday, September 3rd. They issued an "outperform" rating and a $35.00 price target on the stock. One analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, 10x Genomics has an average rating of "Moderate Buy" and an average target price of $25.14.

10x Genomics Price Performance

NASDAQ TXG traded up $0.79 during trading hours on Monday, reaching $14.99. The company's stock had a trading volume of 2,487,468 shares, compared to its average volume of 1,751,117. The firm has a fifty day simple moving average of $15.63 and a 200-day simple moving average of $18.89. 10x Genomics, Inc. has a 52 week low of $12.95 and a 52 week high of $57.90. The stock has a market cap of $1.81 billion, a P/E ratio of -9.80 and a beta of 1.84.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.04. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The company had revenue of $151.65 million during the quarter, compared to the consensus estimate of $158.84 million. During the same period last year, the company earned ($0.51) earnings per share. The firm's revenue was down 1.3% compared to the same quarter last year. On average, research analysts expect that 10x Genomics, Inc. will post -1.4 earnings per share for the current year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.